Exome-wide association study of levodopa-induced dyskinesia in Parkinson’s disease
Abstract Levodopa is the standard long-term dopamine replacement therapy to treat Parkinson’s disease (PD) symptoms. With time, levodopa may induce debilitating dyskinesias (LID), the treatment of which represents a large clinically unmet need. However, time-to-LID onset varies between patients, ref...
Saved in:
Main Authors: | Eva König, Alessandra Nicoletti, Cristian Pattaro, Grazia Annesi, Roberto Melotti, Alessandro Gialluisi, Christine Schwienbacher, Anne Picard, Hagen Blankenburg, Irene Pichler, Nicola Modugno, Marina Ciullo, Teresa Esposito, Francisco S. Domingues, Andrew A. Hicks, Mario Zappia, Peter P. Pramstaller |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Portfolio
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/729fb5b9e7544bd191b10488b78de1e8 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cognitive impairment and levodopa induced dyskinesia in Parkinson’s disease: a longitudinal study from the PACOS cohort
by: Antonina Luca, et al.
Published: (2021) -
Levodopa-induced dyskinesias in Parkinson’s disease: emerging treatments
by: Bargiotas P, et al.
Published: (2013) -
Controlled-release levodopa methyl ester/benserazide-loaded nanoparticles ameliorate levodopa-induced dyskinesia in rats
by: Yang X, et al.
Published: (2012) -
Effects and molecular mechanism of chitosan-coated levodopa nanoliposomes on behavior of dyskinesia rats
by: Cao,Xuebing, et al.
Published: (2016) -
Ranitidine reduced levodopa-induced dyskinesia by remodeling neurochemical changes in hemiparkinsonian model of rats
by: Shi H, et al.
Published: (2015)